株式会社フェニックスバイオ

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity

Nakayama, M. Takagi-Maeda, S. Machino, Y. Nihira, K. Inoue, M. Takahashi, N. Usami, K.
Oncol Rep. 2025 Nov;54(5):155. doi: 10.3892/or.2025.8988.

READ MORE(PUB MED)

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Kawamoto, K. Shimotsuma, Y. Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.

Arch Toxicol. 2025 Sep;99(9):3803-3824. doi: 10.1007/s00204-025-04099-9.

READ MORE(PUB MED)

Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice

Fujita, Yuito Tsutsui, Haruka Hirabayashi, Manabu Shimojo, Tomofumi Tachibana, Tatsuhiko Emoto, Chie Shindoh, Hidetoshi Terao, Kimio Miyake, Taiji
Drug Metab Dispos. 2025 Oct 17;53(12):100185. doi: 10.1016/j.dmd.2025.100185.

READ MORE(PUB MED)

Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

Yano, J. Kawamoto, K. Shimotsuma, Y. Ogata, K. Matsunaga, K. Abe, J. Fukunaga, S. Osimitz, T. G. Lake, B. G. Asano, H.
Regul Toxicol Pharmacol. 2025 Dec;163:105929. doi: 10.1016/j.yrtph.2025.105929.

READ MORE(PUB MED)

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

READ MORE(PUB MED)

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

READ MORE(PUB MED)

Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

READ MORE(PUB MED)

Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

Miyake, T. Fujita, Y. Hirabayashi, M. Komiyama, N. Morita, K. Tachibana, T. Terao, K.
Drug Metab Dispos. 2025 Feb 10;53(4):100050. doi: 10.1016/j.dmd.2025.100050.

READ MORE(PUB MED)

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

Karlsson, I. B. Ekdahl, A. Etchingham-Coll, H. Li, X. Q. Ericsson, C. Ahlqvist, M. Samuelsson, K.
Int J Mol Sci. 2025 Jan 28;26(3):1141. doi: 10.3390/ijms26031141

READ MORE(PUB MED)

Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration

Shishido, Y. Yoshida, T. Oshida, K. Uchida, M.
Pharmacol Res Perspect. 2024 Oct;12(5):e70017. doi: 10.1002/prp2.70017.

READ MORE(PUB MED)

Utility of Chimeric Mice with Humanized Livers for Predicting Hepatic Organic Anion – Transporting Polypeptide 1B (OATP1B) – Mediated Clinical Drug-Drug Interactions

Feng, B. Liang, G. Zetterberg, C. Li, S. Huang, H. Williams, J.Gao, H. Morikawa, Y. Kumar, S.
Drug Metab Dispos. 2024 Aug 5:DMD-AR-2024-001792. doi: 10.1124/dmd.124.001792.

READ MORE(PUB MED)

Chimeric mouse with humanized liver, an emerging tool for the drug development「創薬ツールとしてのヒト肝細胞キメラマウス」

Shimada, T.
Nihon Yakurigaku Zasshi. 2023;158(6):483-489. doi: 10.1254/fpj.23038.

READ MORE(PUB MED)

Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

Miyake, T. Mochizuki, T. Nakagawa, T. Nakamura, M. Emoto, C. Komiyama, N. Hirabayashi, M. Tsuruta, S. Shimojo, T. Terao, K. Tachibana, T.
Br J Pharmacol. 2023 Oct 23. doi: 10.1111/bph.16270.

READ MORE(PUB MED)

Establishment of hyperoxic cell culture system for predicting drug-induced liver injury: reducing accumulated lipids in hepatocytes derived from chimeric mice with humanized liver

Ohtsuki, Y. Sanoh, S. Yamao, M. Kojima, Y. Kotake, Y. Tateno, C.
J Toxicol Sci. 2023;48(2):99-108. doi: 10.2131/jts.48.99.

READ MORE(PUB MED)

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

READ MORE(PUB MED)

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

READ MORE(PUB MED)

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Fukunaga, S. Ogata, K. Eguchi, A. Matsunaga, K. Sakurai, K. Abe, J. Cohen, S. M. Asano, H.
Regul Toxicol Pharmacol. 2022 Oct 6;136:105268. doi: 10.1016/j.yrtph.2022.105268.

READ MORE(PUB MED)

Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties

Aljaber, M. Y. Orie, N. N. Raees, A. Kraiem, S. Al-Jaber, M. Samsam, W. Hamza, M. M. Abraham, D. Kneteman, N. M. Beotra, A. Mohamed-Ali, V. Almaadheed, M.
Future Sci OA. 2022 Jul 7;8(6):FSO805. doi: 10.2144/fsoa-2022-0006. eCollection 2022 Jul.

READ MORE(PUB MED)

Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays

Sato, K. Sanoh, S. Ishida, Y. Tateno, C. Ohta, S. Kotake, Y.
J Toxicol Sci. 2022;47(7):277-288. doi: 10.2131/jts.47.277.

READ MORE(PUB MED)

Elucidation of the species differences of epyrifenacil-induced hepatotoxicity between mice and humans by mass spectrometry imaging analysis in chimeric mice with humanized liver

Matsunaga, K. Abe, J. Ogata, K. Fukunaga, S. Kitamoto, S.
J Toxicol Sci. 2021;46(12):601-609. doi: 10.2131/jts.46.601.

READ MORE(PUB MED)

研究発表

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice

Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration

Utility of Chimeric Mice with Humanized Livers for Predicting Hepatic Organic Anion – Transporting Polypeptide 1B (OATP1B) – Mediated Clinical Drug-Drug Interactions

Chimeric mouse with humanized liver, an emerging tool for the drug development「創薬ツールとしてのヒト肝細胞キメラマウス」

Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

Establishment of hyperoxic cell culture system for predicting drug-induced liver injury: reducing accumulated lipids in hepatocytes derived from chimeric mice with humanized liver

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties

Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays

Elucidation of the species differences of epyrifenacil-induced hepatotoxicity between mice and humans by mass spectrometry imaging analysis in chimeric mice with humanized liver